New antifungals drugs, new approaches and vaccines

Drupal spam blocked by CleanTalk.
Title Antifungal name Trial phase Date
In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida. Manumycin A 5 Dec 2013
Evaluation of the antifungal activity of SCY-078 in combination with other antifungals against Aspergillus strains Ibrexafungerp (SCY-078, MK-3118) 27 Apr 2017
Pharmacodynamics of F901318 against Aspergillus fumigatus in a rabbit model of invasive pulmonary aspergillosis (IPA) F901318 (olorofim) 27 Apr 2017
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of.. Ibrexafungerp (SCY-078, MK-3118) Phase 2 27 Apr 2017
In-vitro activity of F901318 and comparators against clinical isolates of cryptic species of Aspergillus F901318 (olorofim) 27 Apr 2017
Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans. P11-6 24 Apr 2017
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Ibrexafungerp (SCY-078, MK-3118) Phase 2 27 Mar 2017
Pharmacokinetics of the Novel Echinocandin, CD101, in Multiple Animal Species. Biafungin (CD101) 27 Mar 2017
In vitro and in vivo antifungal profile of a novel and long acting inhaled azole, PC945, on Aspergillus fumigatus infection. PC945 13 Mar 2017
Special Issue: Novel Antifungal Drug Discovery General articles 15 Feb 2017